Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 5/20 | 0.72 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.46 |
| ▸ | CPB1 | P15086 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653187 | 0.93 | PTGER4 (0.71) | PTGER4CA1CA2TAS1R3TAS1R1 | |
| SCHEMBL5655171 | 0.93 | PTGER4 (0.75) | PTGER4CA1CA2TAS1R3TAS1R1 | |
| SCHEMBL5657127 | 0.91 | PTGER4 (0.58) | PTGER4MMP8TAS1R3TAS1R1NAMPT | |
| SCHEMBL5652845 | 0.90 | PTGER4 (0.59) | PTGER4CA1CA2MMP8TAS1R3 | |
| SCHEMBL5654830 | 0.90 | PTGER4 (0.56) | PTGER4MMP8TAS1R3TAS1R1NAMPT | |
| SCHEMBL5651439 | 0.89 | PTGER4 (0.58) | PTGER4MMP8TAS1R3TAS1R1NAMPT | |
| SCHEMBL5668471 | 0.88 | PTGER4 (0.55) | PTGER4MMP8TAS1R3TAS1R1NAMPT | |
| SCHEMBL5653336 | 0.88 | PTGER4 (0.55) | PTGER4MMP8TAS1R3TAS1R1NAMPT | |
| SCHEMBL5668462 | 0.88 | PTGER4 (0.55) | PTGER4MMP8TAS1R3TAS1R1NAMPT | |
| SCHEMBL5654420 | 0.87 | PTGER4 (0.74) | PTGER4CA1CA2TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | ASTELLAS PHARMA INC. (JP) | 2007-06-21 | — | — | US | disclosed |
| EP-1697337-A2 | ORNITHINE DERIVATIVES AS PROSTAGLANDIN-E2-AGONISTS OR ANTAGONISTS | Astellas Pharma Inc. (JP) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005061475-A2 | ORNITHINE DERIVATIVES AS PROSTAGLANDIN E2 AGONISTS OR ANTAGONISTS | ASTELLAS PHARMA INC. (JP) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | PTGER4, OXER1, RXFP4 | PTGER4 1/4885CA1 3110/4885CA2 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.